The Medical Science Liaison (MSL) for Cell Therapy & Transplant (CTT) will collaborate directly with the Medical Director and other cross functional stakeholders to support initiation & management of a pivotal clinical study for AlloHeme, a blood based NGS relapse prediction test for post bone marrow transplant AML & MDS patients. Through our innovative portfolio of molecular diagnostics, digital health solutions, AI-powered data and analytics, and patient support services, we partner with healthcare providers, patients, and biopharma organizations to help inform clinical decision-making and improve patient outcomes.